Biomea Fusion announces presentation of preclinical data on icovamenib

Biomea Fusion (BMEA) announced the presentation of preclinical data from its investigational menin inhibitor icovamenib in combination with semaglutide in a T2D animal model. The oral presentation titled “Icovamenib and Semaglutide Combination Therapy Enhances Body Weight Loss and Glycemic Control While Preserving Lean Mass in a Type 2 Diabetes Animal Model,” was presented at the 61st European Association for the Study of Diabetes, EASD, Annual Meeting, which takes place September 15 – 19, 2025, in Vienna, Austria. Presentation Summary: Results: Combination therapy produced significant reductions in fasting and fed blood glucose levels as early as one week, with a 60% mean reduction in fasting blood glucose after two weeks versus semaglutide alone. Oral glucose tolerance test, OGTT, results showed a 50% lower mean glucose AUC compared to semaglutide alone, and a greater than1% mean reduction in HbA1c by Day 28. Combination therapy also reduced insulin resistance and improved beta cell function. Importantly, combination therapy resulted in greater mean body weight loss compared to semaglutide alone, and was driven entirely by fat mass reduction, with preservation of lean mass. Conclusion: We believe these results support the potential of icovamenib to enhance the effectiveness of GLP-1-based therapies by enabling lower doses to achieve the glycemic and weight loss targets, while also preserving lean mass, a highly desirable profile for the potential long-term management of diabetes and obesity.